|
Vaccine Detail
Cancer Vaccine using E7 protein of human papillomavirus 16 and Algammulin |
Vaccine Information |
- Vaccine Name: Cancer Vaccine using E7 protein of human papillomavirus 16 and Algammulin
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0004227
- Type: Subunit vaccine
- Status: Research
- Antigen: Peptide GF001, comprising the H-2Db-restricted minimal CTL epitope of HPV16 E7 protein (Fernando et al., 1998).
- E7
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Adjuvant:
- Immunization Route: subcutaneous injection
|
Host Response |
Mouse Response
- Host Strain: C57BL/6J
- Vaccination Protocol: Mice (8 to 10 per group) were immunized s.c. at the base of the tail with 50 µg of E7GST protein, or 50 µg OVA as control, and 10 µg of Quil-A or 50 µg of Algammulin as adjuvant (Fernando et al., 1998).
- Challenge Protocol: Mice were challenged with 3 x 10^6 cells of EL4.E7 tumor or 2 x 10^6 cells of C3 cells 14 days after the last immunization (Fernando et al., 1998).
- Efficacy: Immunization with E7 and Algammulin (an alum-based adjuvant) induced a Th2-like response and provided no tumor protection (Fernando et al., 1998).
|
References |
Fernando et al., 1998: Fernando GJ, Stewart TJ, Tindle RW, Frazer IH. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model. Journal of immunology (Baltimore, Md. : 1950). 1998; 161(5); 2421-2427. [PubMed: 9725239].
|
|